ChronoScale Corporation Common Stock (NASDAQ:CHRN) Releases Earnings Results

ChronoScale Corporation Common Stock (NASDAQ:CHRN) issued its quarterly earnings results on Wednesday. The company reported ($0.29) EPS for the quarter, FiscalAI reports. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%. The business had revenue of $41.48 million for the quarter.

ChronoScale Corporation Common Stock Trading Up 7.9%

Shares of CHRN opened at $16.05 on Friday. ChronoScale Corporation Common Stock has a 12-month low of $3.50 and a 12-month high of $30.00. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of -2.98 and a beta of 0.98. The stock’s 50-day moving average price is $19.90 and its 200 day moving average price is $18.19. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.06.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc increased its position in ChronoScale Corporation Common Stock (NASDAQ:CHRN) by 104.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,338 shares of the company’s stock after purchasing an additional 1,195 shares during the quarter. Roble Belko & Company Inc owned approximately 0.07% of ChronoScale Corporation Common Stock worth $25,000 at the end of the most recent quarter. 6.42% of the stock is currently owned by institutional investors.

ChronoScale Corporation Common Stock News Roundup

Here are the key news stories impacting ChronoScale Corporation Common Stock this week:

• Positive Sentiment: Northland Securities’ outlook implies significant potential appreciation, with the firm retaining its Outperform rating and $32 target. The analyst forecasts a return to quarterly profitability with $0.16 EPS in Q4 2028, suggesting improving earnings power over time. Northland Securities analyst estimates
• Neutral Sentiment: Northland expects ChronoScale to remain unprofitable across the forecast period, including estimated losses of $0.07 per share in Q2 2027, $0.10 in Q3 2027, $0.39 for fiscal 2027, and $0.15 for fiscal 2028. The estimates indicate a gradual path toward profitability but continued execution risk. ChronoScale earnings estimates
• Negative Sentiment: ChronoScale reported a fiscal first-quarter loss of $0.29 per share on $41.48 million in revenue. Its negative net margin of 135.66% and negative return on equity of 197.81% underscore substantial ongoing losses and may weigh on the stock until growth translates into better profitability. ChronoScale Reports Fiscal First Quarter 2027 Results

Analyst Ratings Changes

A number of equities analysts recently issued reports on CHRN shares. Northland Securities started coverage on shares of ChronoScale Corporation Common Stock in a research report on Friday, September 18th. They set an “outperform” rating and a $32.00 target price on the stock. Weiss Ratings upgraded shares of ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, October 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.00.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.